Characterization of a novel and selective cannabinoid CB(1) receptor inverse agonist, Imidazole 24b, in rodents.

Characterization of a novel and selective cannabinoid CB(1) receptor inverse agonist, Imidazole 24b, in rodents. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Characterization of a novel and selective cannabinoid CB(1) receptor inverse agonist, Imidazole 24b, in rodents. Abstract Text:

Lauren P Shearman,D Sloan Stribling,Ramon E Camacho,Kimberly M Rosko,Junying Wang,Sharon Tong,Yue Feng,Donald J Marsh,Hong Yu,Xiaoming Guan,Stephanie K Spann,Douglas J Macneil,Tung M Fong,Joseph M Metzger,Mark T Goulet,William K Hagmann,Christopher W Plummer,Paul E Finke,Sander G Mills,Shrenik K Shah,Quang Truong,L H T Van der Ploeg,D Euan Macintyre,Alison M Strack,

We document in vitro and in vivo effects of a novel, selective cannabinoid CB(1) receptor inverse agonist, Imidazole 24b (5-(4-chlorophenyl)-N-cyclohexyl-4-(2,4-dichlorophenyl)-1-methyl-imidazole-2-carboxamide). The in vitro binding affinity of Imidazole 24b for recombinant human and rat CB(1) receptor is 4 and 10 nM, respectively. Imidazole 24b binds to human cannabinoid CB(2) receptor with an affinity of 297 nM; in vitro, it is a receptor inverse agonist at both cannabinoid CB(1) and CB(2) receptors as it causes a further increase of forskolin-induced cAMP increase. Oral administration of Imidazole 24b blocked CP-55940-induced hypothermia, demonstrating cannabinoid CB(1) receptor antagonist efficacy in vivo. Using ex vivo autoradiography, Imidazole 24b resulted in dose-dependent increases in brain cannabinoid CB(1) receptor occupancy (RO) at 2h post-dosing in rats, indicating that approximately 50% receptor occupancy is sufficient for attenuation of receptor agonist-induced hypothermia. Imidazole 24b administered to C57Bl/6 mice and to dietary-induced obese (DIO) Sprague-Dawley rats attenuated overnight food intake with a minimal effective dose of 10 mg/kg, p.o. Administration had no effect in cannabinoid CB(1) receptor-deficient mice. DIO rats were dosed orally with vehicle, Imidazole 24b (1, 3 or 10 mg/kg), or dexfenfluramine (3 mg/kg) for 2 weeks. At 3 mg/kg, Imidazole 24b reduced cumulative food intake, leading to a non-significant decrease in weight gain. Imidazole 24b at 10 mg/kg and dexfenfluramine treatment inhibited food intake and attenuated weight gain. These findings suggest that selective cannabinoid CB(1) receptor inverse agonists such as Imidazole 24b have potential for the treatment of obesity.

Characterization of a novel and selective cannabinoid CB(1) receptor inverse agonist, Imidazole 24b, in rodents. Publishing Authors By Initials

LP Shearman,DS Stribling,RE Camacho,KM Rosko,J Wang,S Tong,Y Feng,DJ Marsh,H Yu,X Guan,SK Spann,DJ Macneil,TM Fong,JM Metzger,MT Goulet,WK Hagmann,CW Plummer,PE Finke,SG Mills,SK Shah,Q Truong,LH Van der Ploeg,DE Macintyre,AM Strack,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Characterization of a novel and selective cannabinoid CB(1) receptor inverse agonist, Imidazole 24b, in rodents. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: European journal of pharmacology

VOLUME: 579

Page Numbers: 215-24

Journal Abbreviation: Eur. J. Pharmacol.

ISSN: 0014-2999

DAY: 25

MONTH: 10

YEAR: 2007

Characterization of a novel and selective cannabinoid CB(1) receptor inverse agonist, Imidazole 24b, in rodents. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 1254354

Characterization of a novel and selective cannabinoid CB(1) receptor inverse agonist, Imidazole 24b, in rodents. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Characterization of a novel and selective cannabinoid CB(1) receptor inverse agonist, Imidazole 24b, in rodents. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Characterization of a novel and selective cannabinoid CB(1) receptor inverse agonist, Imidazole 24b, in rodents.

AFFILIATION: Department of Pharmacology, Merck Research Laboratories, Rahway, NJ 07065, United States.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Eur J Pharmacol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents Related Publications

• Activities of Arabidopsis sinapoylglucose:malate sinapoyltransferase shed light on functional diversification of serine carboxypeptidase-like acyltransferases.
• Characterization of a novel and selective cannabinoid CB(1) receptor inverse agonist, Imidazole 24b, in rodents.
• Electrical stimulation-supported voice exercises are superior to voice exercise therapy alone in patients with unilateral recurrent laryngeal nerve paresis: Results from a prospective, randomized clinical trial.
• Imaging as a tool in drug development.
• Metabolite profiling of mycorrhizal roots of Medicago truncatula.
• Metformin: A review.
• Ml03 work injuries - not always what they seem.
• Obesity and the central nervous system.
• Reversible phosphorylation of Drp1 by cyclic AMP-dependent protein kinase and calcineurin regulates mitochondrial fission and cell death.
• The tempting effect of forbidden foods. High calorie content evokes conflicting implicit and explicit evaluations in restrained eaters.
• Understanding the relations between different forms of racial prejudice: a cognitive consistency perspective.
• [Not Available.]
• [Not Available.]